Drug Type Prophylactic vaccine, Fusion protein |
Synonyms Recombinant SARSCoV2 Fusion Protein Vaccine, Recombinant coronavirus fusion protein vaccine Livzon Mabpharm/Institute of Biophysics Chinese Academy of Sciences, V01 Livzon Mabpharm/Institute of Biophysics Chinese Academy of Sciences + [3] |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (02 Sep 2022), |
RegulationEmergency Use Authorization (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | CN | 02 Sep 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | RU | 25 Aug 2021 | |
COVID-19 | Phase 3 | ID | 25 Aug 2021 | |
COVID-19 | Phase 3 | PH | 25 Aug 2021 |
NCT05096832 (Pubmed) Manual | Phase 3 | 10,218 | (ozxwtcvotp) = ehyumkvkcr cteuakbjie (nswgvwydji ) View more | Positive | 10 Jun 2022 | ||
Placebo | (ozxwtcvotp) = guqbfitwos cteuakbjie (nswgvwydji ) |